Molecular Partners announced at its extraordinary general meeting held on October 31, 2017, the shareholders of the company approved the election of William (Bill) Burns, former CEO of Roche Pharmaceuticals as new member of the Board of Directors with large majorities. The Board of Directors has appointed Bill Burns Vice-Chairman and will nominate him for election as Chairman of the Board of Directors at the annual general meeting 2018. Bill Burns brings to the company vast experience in the development and commercialization of drugs, particularly in oncology, and extensive knowledge of pharmaceutical industry operations.